Logo

American Heart Association

  106
  0


Final ID: MDP1199

High-normal Blood Pressure (130-139/85-89mmHg) is Associated with an Increased Risk of Mortality

Abstract Body (Do not enter title and authors here):
Background The relationship between high-normal blood pressure (BP) and mortality lacks high-quality evidence based on large population cohort. The aim of this study was to comprehensively investigate the association of high-normal BP and its trajectory with all-cause and cause-specific mortality.
Methods In a community-based population cohort from the China Health Evaluation And risk Reduction through nationwide Teamwork (ChinaHEART) project, 3,598,940 participants aged 35-75 years with baseline BP were included. High-normal BP was defined as a systolic blood pressure (SBP) of 130-139 mmHg and/or a diastolic blood pressure (DBP) of 85-89 mmHg at baseline. Four trajectories of BP change were identified in 105,894 participants included in the study, who had more than 2 follow-up BP measurements, using latent mixture modeling. Among them, high-normal-increasing was defined as an increase in SBP from 130-139 at baseline to over 140 at the last follow-up.
Findings Compared with the optimal BP group (SBP < 120 mmHg and DBP < 80 mmHg, [18.1%]), participants with high-normal BP (18.7%) had a 4% increase in all-cause mortality risk (hazard ratio [HR] 1.04, 95% confidence interval [CI]: 1.01-1.07) and a 28% increase in CVD mortality risk (HR 1.28, 95% CI: 1.21-1.34), with the greatest increase in mortality risk observed from hemorrhagic stroke (HR 1.75, 95% CI: 1.55-1.98). Among BP trajectories, compared with participants with optimal-stable BP (25.3%), those with high-normal-increasing BP (3.5%) had a 25% increase in all-cause mortality risk (HR 1.25, 95% CI: 1.00-1.54) and a 67% increase in CVD mortality risk (HR 1.66, 95% CI: 1.21-2.30), with the greatest increase in mortality risk also observed from hemorrhagic stroke (HR 3.15, 95% CI: 1.38-7.20). In our study cohort, approximately 0.7% and 1.3% of all-cause mortality was attributable to the high-normal BP at baseline and high-normal-increasing BP trajectory, respectively.
Interpretation Individuals presenting high-normal BP at baseline or high-normal-increasing BP trajectory afterward exhibited a significantly elevated mortality risk, which is most pronounced for hemorrhagic stroke. Early management of BP in patients with high-normal BP is crucial for the prevention and treatment of hypertension.
  • Li, Zhiwei  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Lu, Jiapeng  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Li, Xi  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Zhang, Weili  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Liu, Mengmeng  ( Central China Subcenter of National Center for Cardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central-China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University , Zhengzhou , China )
  • Chen, Bowang  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Wu, Yuelin  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Jia, Hui  ( Central China Subcenter of National Center for Cardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central-China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University , Zhengzhou , China )
  • Geng, Ruirui  ( Central China Subcenter of National Center for Cardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central-China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University , Zhengzhou , China )
  • Zhang, Xiaoyan  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Yang, Yang  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Cui, Jianlan  ( National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Author Disclosures:
    Zhiwei Li: DO NOT have relevant financial relationships | jiapeng lu: No Answer | xi li: No Answer | weili zhang: DO NOT have relevant financial relationships | Mengmeng Liu: No Answer | Bowang Chen: DO NOT have relevant financial relationships | yuelin wu: No Answer | hui jia: No Answer | ruirui geng: DO NOT have relevant financial relationships | xiaoyan zhang: No Answer | yang yang: No Answer | jianlan CUI: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Threats of Hypertension to Life and Healthy Organ Function

Sunday, 11/17/2024 , 09:30AM - 10:45AM

Moderated Digital Poster Session

More abstracts on this topic:
Adverse Pregnancy Outcomes and Offspring Cardiovascular Health in Early Adulthood

Lam Emily, Notterman Daniel, Lloyd-jones Donald, Allen Norrina, Shah Nilay, Gauen Abigail, Khan Sadiya, Freedman Alexa, Stein James, Venkatesh Kartik, Tawa Elisabeth, Savas Hacer, Goldman Noreen

Absence of standard modifiable risk factors (SMuRF-less) among 5002 Middle Eastern patients with atherosclerotic cardiovascular disease: (Interim analysis from the Jo-SMuRF Study)

Aldalal'ah Mo'men, Hammoudeh Ayman, Hamza Ibrahem, Alqudah Mohammad, Khasawneh Hasan, Alomari Sawsan, Alomari Ahmad, H. Assaf Sarah, Zaqqa Ayah, Khatatbeh Moawiah

More abstracts from these authors:
Prediction of Cardiovascular Disease Risk in Chinese Elderly from 2025 to 2050: A Simulation Study Based on a National Cohort

Wu Yi, Jin Bolin, Li Xi

Comparative Effectiveness between Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on Mortality: a Nationwide, Population-based, Prospective Cohort Study in China

Wang Yunfeng, Xu Wei, Song Lijuan, Wang Chunqi, Wu Yi, Krumholz Harlan, Li Xi, Hu Shengshou, Guo Weihong, Hao Yang, Zheng Xin, Zhang Haibo, Yang Yang, Chen Bowang, Zhang Xiaoyan, Cui Jianlan

You have to be authorized to contact abstract author. Please, Login
Not Available